Good day, 360!

Here are our top investing ideas today. And don’t forget to join us in Market Masters – the hottest trading room around 🔥. Be the best prepared trader on the Street!

FOCUS LIST🔎

ADTX – Up over 80% in pre after amended merger agreement with Evofem, targeting September 30 closing

GDTC – Up over 40% in pre after acquiring license and certain assets  of Cellsafe International Sdn Bhd (In Liquidation) (CISB), a Malaysian cord blood bank for  cash consideration

GTLB – Up over 15% in pre after reports it’s exploring a sale, after attracting acquisition interest

DEAL ENDS @ MIDNIGHT

💥GET MARKET NAVIGATOR & ATOMIC TRADES💥

BUNDLE & SAVE BIG HERE!

HOTLIST🔥

ADTX – Up over 80% in pre after amended merger agreement with Evofem, targeting September 30 closing 

Aditxt Inc. (ADTX) is a biotech company that engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems.

In the pre-market this morning, the company announced an amended merger agreement with Evofem, targeting September 30 closing.

This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem’s future success, including interim financing needs.

The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substituting cash for Aditxt’s common stock as the consideration for Evofem’s common stock in the merger and additional changes relating to it.

Evofem recently announced the acquisition of SOLOSEC® (secnidazole) 2g oral granules from Lupin Limited. Under the transaction terms, Lupin can receive a potential total consideration of up to $84 million based on future contingent milestones.

“Aditxt and Evofem share a common vision in recognizing and valuing innovations like SOLOSEC that need additional support to reach their full potential,” said Saundra Pelletier, Chief Executive Officer of Evofem.

Stock of ADTX traded up over 80% in the pre-market in reaction to the news.

The $2.45 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.75, $3, $3.30 and then the pre-market high at $3.36. Beyond that, $3.50 and $4 come into play.

Below $2.45, targets to the downside are $2.20, $2 and then a gap fill at $1.60.

GDTC – Up over 40% in pre after acquiring license and certain assets  of Cellsafe International Sdn Bhd (In Liquidation) (CISB), a Malaysian cord blood bank for  cash consideration 

CytoMed Therapeutics Limited (GDTC) is a pre-clinical biopharmaceutical company that focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

In the pre-market this morning the company announced that its wholly owned subsidiary, IPSC Depository Sdn Bhd acquired the license and certain assets of Cellsafe International Sdn Bhd (In Liquidation) (“CISB”), a Malaysian cord blood bank for a cash consideration of approximately RM 2.3 million or US$ 490,000 to be funded from internal cash resources.

The price consideration includes a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment with more than 12,000 cord blood units (“CBUs”) and two freehold real estate properties totaling 189 square metres in which the operation is situated.

“This acquisition is to unlock the therapeutic potential of umbilical cord blood and adds strategic capital to our vision to develop cytotoxic γδ T cells for cancer treatment” said Peter Choo, Chairman of CytoMed “We aim to be the pre-eminent player in the γδ T cell technology with capabilities to produce highly viable γδ T cells from three key sources namely from adult peripheral blood mononuclear cells, from iPSC and soon, from the small amount of cord blood from the cryopreserved CBUs.”

The stock traded up over 40% in the pre-market in reaction to the news.

The $2.40 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.75, $3, $3.20, $3.50 and then the pre-market high at $4.97.

Below $2.40, targets to the downside are $2.25, $2 and then a gap fill at $1.96.

GTLB – Up over 15% in pre after reports it’s exploring a sale, after attracting acquisition interest 

GitLab Inc. (GTLB) develops software for the software development lifecycle in the United States and internationally. It offers GitLab, a DevOps platform, which is a single application that leads to faster cycle time and allows visibility throughout and control over various stages of the DevOps lifecycle.

Overnight, it was reported  that the company was exploring a sale, after attracting acquisition interest,  according to people familiar with the matter.

GitLab, which has a market value of about $8 billion, is working with investment bankers on a sale process that has attracted interest from peers, including cloud monitoring firm Datadog, the sources said.

Any deal is still weeks away and no agreement is certain, the sources said, requesting anonymity because the matter is confidential.

Gitab’s early investors include Google parent Alphabet.

The stock traded up over 15% in the pre-market in reaction to the reports.

The first target for bulls is the pre-market high at $59.

Beyond that targets to the upside are $60, $62, $64 and $66.

Below $59, targets to the downside are $57.50, $56.60, $56, $54, $52 and then a gap fill at $50.66.

MARKET NEWS 📰

P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!

Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull